Gilead Sciences | GILD - Sales Revenues

Stock Price
149.37
Daily Change
3.14 2.15%
Monthly
23.08%
Yearly
52.36%
Q1 Forecast
137.58

Gilead Sciences reported $7.8B in Sales Revenues for its fiscal quarter ending in September of 2025.





Sales Change Date
AbbVie USD 16.62B 840M Dec/2025
Agios Pharmaceuticals USD 12.9M 450K Sep/2025
ALKERMES USD 394.2M 3.5M Sep/2025
Alnylam Pharmaceuticals USD 1.25B 476.31M Sep/2025
Amgen USD 9.9B 340M Dec/2025
Biogen USD 2.28B 250M Dec/2025
BioMarin Pharmaceutical USD 776M 49M Sep/2025
Bristol-Myers Squibb USD 12.5B 300M Dec/2025
Eli Lilly USD 19.3B 1.7B Dec/2025
Gilead Sciences USD 7.8B 700M Sep/2025
GlaxoSmithKline GBP 8.62B 73M Dec/2025
Glaxosmithkline GBP 11.52B 3.54B Sep/2025
Incyte USD 1.37B 310M Sep/2025
J&J USD 24.6B 610M Dec/2025
Merck USD 16.4B 880M Dec/2025
Moderna USD 1.02B 878M Sep/2025
Neurocrine Biosciences USD 794.9M 107.4M Sep/2025
Novartis USD 13.91B 144M Sep/2025
Pfizer USD 17.58B 880M Dec/2025
PTC Therapeutics USD 211M 32.1M Sep/2025
Regeneron Pharmaceuticals USD 3.88B 130M Dec/2025
Sanofi EUR 11.3B 1.13B Dec/2025
Sarepta Therapeutics USD 399.4M 211.69M Sep/2025
United Therapeutics USD 799.5M 900K Sep/2025
Vertex Pharmaceuticals USD 3.08B 120M Sep/2025